United Therapeutics Corporation filed its Form 10-Q for the quarterly period ended June 30, 2026, with the U.S. Securities and Exchange Commission on August 5, 2026, reporting net income of $333.0 million for the second quarter and $607.9 million for the first half of the year.

Key Highlights

  • Q2 2026 total revenues: $783.3 million, compared with $798.6 million in Q2 2025, according to the filing.
  • Q2 2026 net income: $333.0 million, up from $309.5 million in the prior-year quarter, the company disclosed.
  • Diluted EPS for Q2 2026: $7.27, versus $6.41 in Q2 2025, as reported in the filing.
  • Six-month net income: $607.9 million for the six months ended June 30, 2026, compared with $631.7 million for the same period in 2025.
  • Total assets: $7,220.1 million as of June 30, 2026, down from $7,880.0 million at December 31, 2025.
  • Treasury stock increased: 35,352,483 shares held as of June 30, 2026, versus 32,809,088 shares at December 31, 2025, reflecting share repurchase activity.
  • Shares outstanding: 42,890,692 as of July 29, 2026, the filing stated.

United Therapeutics Second-Quarter and Half-Year 2026 Financial Results

United Therapeutics Corporation (Nasdaq Global Select Market: UTHR), a Delaware public benefit corporation headquartered in Silver Spring, Maryland, reported total revenues of $783.3 million for the three months ended June 30, 2026, compared with $798.6 million for the same period in 2025. For the six months ended June 30, 2026, total revenues were $1,564.8 million, compared with $1,593.0 million in the prior-year period, according to the filing.

The company disclosed total operating expenses of $452.5 million for Q2 2026, including cost of sales of $99.5 million, research and development expenses of $146.3 million, and selling, general, and administrative expenses of $206.7 million. Operating income for the quarter was $330.8 million, versus $364.5 million in Q2 2025. Income tax expense for Q2 2026 was $39.7 million, compared with $98.9 million in the prior-year quarter. The filing reported interest income of $31.5 million for Q2 2026, down from $51.3 million a year earlier.

On the balance sheet, the company reported total stockholders' equity of $6,400.3 million as of June 30, 2026, compared with $7,096.2 million at December 31, 2025. Cash and cash equivalents stood at $1,803.2 million, up from $1,557.1 million at year-end 2025. Retained earnings were $9,164.8 million at June 30, 2026, compared with $8,556.9 million at December 31, 2025. Treasury stock was carried at $(5,644.9) million as of June 30, 2026, reflecting an increase from $(4,260.4) million at December 31, 2025. Share-based compensation contributed $43.4 million to additional paid-in capital in Q2 2026, and stock option exercises added $126.3 million during the same quarter, the company disclosed.

What Was Disclosed

United Therapeutics filed its unaudited quarterly report covering the period ended June 30, 2026, disclosing revenues, earnings, balance sheet figures, and equity activity for both the second quarter and first half of fiscal 2026, with comparisons to the corresponding prior-year periods.